Melnick Lab

Publications

2017

is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells., H. Kunimoto; A.Sophia McKenney; C. Meydan; K. Shank; A. Nazir; F. Rapaport; B. Durham; F.E. Garrett-Bakelman; E. Pronier; A.H. Shih; A. Melnick; J. Chaudhuri; R.L. Levine, Blood, 2017 Mar 30, 129, 13, p.1779-1790, (2017) PubMed

MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia., N.S. Saba; D.H. Wong; G. Tanios; J.R. Iyer; P. Lobelle-Rich; E.L. Dadashian; D. Liu; L. Fontan; E.K. Flemington; C.M. Nichols; C. Underbayev; H. Safah; A. Melnick; A. Wiestner; S.E.M. Herman, Cancer Res, 2017 12 15, 77, 24, p.7038-7048, (2017) PubMed

Genetic and epigenetic inactivation of controls mTORC1 and response to EZH2 inhibition in follicular lymphoma., E. Oricchio; N. Katanayeva; M.Christine Donaldson; S. Sungalee; J.P. Pasion; W. Béguelin; E. Battistello; V.R. Sanghvi; M. Jiang; Y. Jiang; M. Teater; A. Parmigiani; A.V. Budanov; F.Chun Chan; S.P. Shah; R. Kridel; A.M. Melnick; G. Ciriello; H.G. Wendel, Sci Transl Med, 2017 06 28, 9, 396, p., (2017) PubMed

Untangling the Web of Lymphoma Somatic Mutations., M. Teater; A. Melnick, Cell, 2017 10 05, 171, 2, p.270-272, (2017) PubMed

CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas., Y. Jiang; A. Ortega-Molina; H. Geng; H.Y. Ying; K. Hatzi; S. Parsa; D. McNally; L. Wang; A.S. Doane; X. Agirre; M. Teater; C. Meydan; Z. Li; D. Poloway; S. Wang; D. Ennishi; D.W. Scott; K.R. Stengel; J.E. Kranz; E. Holson; S. Sharma; J.W. Young; C.S. Chu; R.G. Roeder; R. Shaknovich; S.W. Hiebert; R.D. Gascoyne; W. Tam; O. Elemento; H.G. Wendel; A.M. Melnick, Cancer Discov, 2017 01, 7, 1, p.38-53, (2017) PubMed

Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells., L.P. Vu; C. Prieto; E.M. Amin; S. Chhangawala; A. Krivtsov; N. Calvo-Vidal; T. Chou; A. Chow; G. Minuesa; S.Mi Park; T.S. Barlowe; J. Taggart; P. Tivnan; R.P. Deering; L.P. Chu; J.A. Kwon; C. Meydan; J. Perales-Paton; A. Arshi; M. Gönen; C. Famulare; M. Patel; E. Paietta; M.S. Tallman; Y. Lu; J. Glass; F.E. Garret-Bakelman; A. Melnick; R. Levine; F. Al-Shahrour; M. Järås; N. Hacohen; A. Hwang; R. Garippa; C.J. Lengner; S.A. Armstrong; L. Cerchietti; G.S. Cowley; D. Root; J. Doench; C. Leslie; B.L. Ebert; M.G. Kharas, Nat Genet, 2017 Jun, 49, 6, p.866-875, (2017) PubMed

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in - and -Mutant Acute Myeloid Leukemia., A.H. Shih; C. Meydan; K. Shank; F.E. Garrett-Bakelman; P.S. Ward; A.M. Intlekofer; A. Nazir; E.M. Stein; K. Knapp; J. Glass; J. Travins; K. Straley; C. Gliser; C.E. Mason; K. Yen; C.B. Thompson; A. Melnick; R.L. Levine, Cancer Discov, 2017 05, 7, 5, p.494-505, (2017) PubMed

CD99 is a therapeutic target on disease stem cells in myeloid malignancies., S.S. Chung; W.S. Eng; W. Hu; M. Khalaj; F.E. Garrett-Bakelman; M. Tavakkoli; R.L. Levine; M. Carroll; V.M. Klimek; A.M. Melnick; C.Y. Park, Sci Transl Med, 2017 01 25, 9, 374, p., (2017) PubMed

2016

EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis., W. Béguelin; M. Teater; M.D. Gearhart; M.Teresa Cal Fernández; R.L. Goldstein; M.G. Cardenas; K. Hatzi; M. Rosen; H. Shen; C.M. Corcoran; M.Y. Hamline; R.D. Gascoyne; R.L. Levine; O. Abdel-Wahab; J.D. Licht; R. Shaknovich; O. Elemento; V.J. Bardwell; A.M. Melnick, Cancer Cell, 2016 08 08, 30, 2, p.197-213, (2016) PubMed

miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis., G.A. Kozloski; X. Jiang; S. Bhatt; J. Ruiz; F. Vega; R. Shaknovich; A. Melnick; I.S. Lossos, Blood, 2016 06 09, 127, 23, p.2856-66, (2016) PubMed